Monday, March 20, 2017 10:40:34 AM
Marketwired MarketwiredMarch 20, 2017Comment
DOVER, DE--(Marketwired - Mar 20, 2017) - Metatron ( OTC PINK : MRNJ ) announces its plan to release the new and revamped Canniboids app during the annual cannabis traffic surge, 4/20 (April 20th, 2017). Cannaboids.com, an Organic Nutraceuticals Portal, was designed for medical marijuana patients to have the resources to find the latest CBD news and connect to legal dispensaries. History has shown the weeks leading up to April 20th, dispensaries around the country show a significant increase in traffic and cannabis sales.
The Cannaboids app was created by Metatron's subsidiary, i-Mobilize app division and was the pioneer to put any Hemp related app on iTunes, and this was the first app to market CBD based products exclusively. The app is based on Metatron's CDB portal and brand, cannaboids.com.
Similar to WeedMaps, the #1 Medical Marijuana app with an estimated $400k a month in sales according to Fast Company, Metatron's app has provided users with access and reviews to distributors of cannabinoid based products. The difference is the company's app provides audio and video content and only feature products legal in all 50 states and most countries.
In recent news, it is stated that legal marijuana sales are projected to reach $20.6 billion by 2020, a significant increase from its current $7.4 billion level.
CBD is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid compound that may have medical benefits. CBD can be made from the mature stalks of the industrial hemp plants and can be legally imported into the United States under Federal Law. Scientific and clinical studies underscore CBD's potential as a treatment for a wide range of conditions, including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. It is important to note that CBD is not approved for the diagnosis, cure, mitigation, treatment, or prevention of any disease.
Mobile Rebranding
The Company, through its mobile division i-Mobilize, plans to relaunch their mobile business in the specific areas of mobile encryption and security, and mobile applications for the growing cannabis and marijuana market. Under this new goal, the Company will keep its focus on a couple of dynamic concepts within the mobile market, and will look to reduce or shelve other projects to the back burner, which may be a smart move as to keep them focused on one or two projects at a time.
The Company has experience in developing over 2000+ mobile applications in the past years with over 3.5 million in sales.
Download Apps
People interested can view and download our current live apps focused on mental health and wellness by visiting the app stores below. We plan to update these apps in our upcoming relaunch, and will be adding a couple more to our list. Stay tuned!
iTunes: https://itunes.apple.com/us/artist/i-mobilize-inc./id325075390
Google Play: https://play.google.com/store/apps/developer?id=Metatron+Inc
Facebook: http://www.facebook.com/metatroninc
Twitter: http://twitter.com/metatroninc
News: http://metatroninc.com/blog
Recent MRNJ News
- Metatron Apps Unveils "Dr. AI" Health Assistant for Personalized Health Support • InvestorsHub NewsWire • 01/23/2024 01:23:40 PM
- Metatron Pioneers AI-driven Content Discovery and Issues Reverse Split Moratorium • InvestorsHub NewsWire • 12/12/2023 04:59:50 PM
- Alternative to AI-Powered Apps As ChatGPT Pauses Signups • AllPennyStocks.com • 11/20/2023 03:00:00 PM
- Alternative to AI-Powered Apps As ChatGPT Pauses Signups • AllPennyStocks.com • 11/20/2023 03:00:00 PM
- Firm Pioneers AI-Powered App with Real-Time Stock Insights • AllPennyStocks.com • 10/30/2023 06:30:00 PM
- Company Looks to Revolutionze Legal Communication with AI • AllPennyStocks.com • 09/25/2023 04:50:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM